undefined - HealthTree for AML

AML Clinical Trials

Here you will find articles that keep you up to date on the newest AML research that AML experts are recruiting for. AML research studies called clinical trials are all about drug development. Drugs must go through many phases of testing to receive FDA approval in order to be prescribed to patients by doctors. Joining a clinical trial for your AML has the potential to provide you with cutting-edge treatment that is not yet widely available to the general public.

In addition to drug development, AML research aims to answer important questions like "what is AML?", "what causes AML?", "is AML genetic?" and "how do we improve AML survival?"

There are over 300 AML research trials actively recruiting patients, which is more than any other leukemia. These articles will keep you informed on the latest clinical trials that are recruiting and the types of new drug therapies that are being studied for the treatment of AML.

Results for Briquilimab, a Well Tolerated Conditioning Agent Used Before Transplant

June 06, 2023

Briquilimab has shown it is a safe and well-tolerated conditioning agent for older patients receiving an allogeneic hematopoietic cell transplantation.

New Drug, EP0042, To Treat FLT-3 Resistance

May 25, 2023

Ellipses Pharma is a drug company that works to accelerate cancer treatment through innovative drug models.

Phase 2 For Ziftomenib Begins for NPM1 Mutated AML

March 05, 2023

Phase 2 of the KOMET-001 trial has dosed its first set of patients. This is a continuation of a trial testing the efficacy of Ziftomenib.

ASH 2022: Revumenib Leads to Long-Lasting Responses in KMT2Ar(MLLr) and NPM1-Mutated AML

December 14, 2022

revumenib

ASH 2022: Final Results of the VIALE-A Trial Assessing Venetoclax Plus Azacitidine

December 12, 2022

The long-term follow-up of the VIALE-A study shows that venetoclax and azacitidine are better in terms of overall survival compared to azacitidine alone.